Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey
Dermatologic Therapy Dec 11, 2017
Potenza MC, et al. - The drug survival and efficacy of different anti-TNF agents underwent a comparative analysis in this study, among psoriasis (PsO) and psoriatic arthritis (PsA) patients. The inference drawn was that adalimumab could be the best therapeutic option over other anti-TNF agents for the treatment of PsO and PsA patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
